Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

NCT01975142 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT01975142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01975142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Completed
Start date
November 7, 2013
Completion date
January 21, 2019
Enrollment
155 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, her2 negative primary tumor